View Financial HealthTechno Drugs 配当と自社株買い配当金 基準チェック /26Techno Drugs配当を支払う会社であり、現在の利回りは2.25%で、収益によって十分にカバーされています。主要情報2.2%配当利回り0%バイバック利回り総株主利回り2.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向62%最近の配当と自社株買いの更新お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.お知らせ • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladeshお知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025お知らせ • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.お知らせ • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 TECHNODRUGが配当金を支払っている期間は 10 年未満です。増加する配当: TECHNODRUGは2年間のみ配当金を支払っており、それ以降は支払額が減少しています。配当利回り対市場Techno Drugs 配当利回り対市場TECHNODRUG 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (TECHNODRUG)2.2%市場下位25% (BD)0.7%市場トップ25% (BD)3.4%業界平均 (Pharmaceuticals)3.7%アナリスト予想 (TECHNODRUG) (最長3年)n/a注目すべき配当: TECHNODRUGの配当金 ( 2.25% ) はBD市場の配当金支払者の下位 25% ( 0.74% ) よりも高くなっています。高配当: TECHNODRUGの配当金 ( 2.25% ) はBD市場の配当金支払者の上位 25% ( 3.35% ) と比較すると低いです。株主への利益配当収益カバレッジ: TECHNODRUGの配当金は、合理的な 配当性向 ( 62.1% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: TECHNODRUGは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YBD 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/03 13:10終値2026/07/02 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Techno Drugs Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
お知らせ • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh
お知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
お知らせ • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.
お知らせ • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024
New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.
Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.